Soin Neuroscience and BIOTRONIK Neuro announced a research collaboration to advance personalized spinal cord stimulation (SCS) tuning using Soin Neuroscience’s proprietary waveform technology.

Led by Amol Soin, M.D., Founder and CEO of Soin Neuroscience, the collaboration will evaluate Soin’s new methods of stimulation optimization. This research initiative is designed to assess Soin’s novel adaptive programming strategies, waveforms, and algorithms informed by observed therapy responses, with the goal of improving patient outcomes in the management of chronic pain.

“While spinal cord stimulation is an established therapy, variability in individual patient response remains a significant challenge,” said Dr. Soin. “Building upon years of prior research, this collaboration allows us to further investigate personalized stimulation tuning approaches using our new waveforms that incorporate iterative optimization and advanced programming flexibility to better align therapy with each patient’s unique needs.”

The Prospera SCS System provides a versatile platform for advanced therapy programming through its BioArc stimulation engine and remote programming capabilities, which support proprietary programming strategies and enable investigation of novel therapy paradigms.

“We are pleased to collaborate with Soin Neuroscience on this important research initiative,” said Todd Langevin, President at BIOTRONIK Neuro. “This work reflects our continued commitment to advancing neuromodulation science and expanding the potential of personalized therapy approaches in support of successful SCS outcomes.”